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BACKGROUND AND OBJECTIVES. ZD1839 is a selective and potent inhibitor of the tyrosine 
kinase associated with the epidermal growth factor receptor (EGFR). Its clinical efficacy has 
been demonstrated for several malignancies. As EGFR has also been reported to be 
expressed in some glioblastoma (GBM) tumor cells, we studied the effect of ZD1839 on the 
viability and growth capacity of glioblastoma tumor cells in vitro. 
METHODS. Cells from the GBM cell lines U251, T98G, A172, or freshly isolated GBM cells 
from a patient or fibroblasts were cultured during 1, 2, 3 or 6 days in the presence of different 
concentrations of ZD1839. At the end of the culture, the viability of the remaining GBM cells 
was analyzed with the MTT assay. In other experiments, GBM cells were washed after 24 
hours culture in the presence of ZD1839, and were further cultured for 5 days in the absence 
of ZD1839, before viability was analyzed. 
RESULTS. Addition of different concentrations of ZD1839 for 1 or 2 days had no effect on the 
viability and growth of the GBM cells. Prolonged exposure of GBM cells to higher 
concentrations of ZD1839 (10 uM) resulted in a small reduction of the in vitro expansion of the 
GBM cells as compared to the control cultures. 
CONCLUSION. Using in vitro culture systems of cell lines and freshly isolated GBM cells of 
unknown EGFR status, we could not demonstrate a direct cytotoxic of cytostatic effect of 
ZD1839 on cell viability or growth, except under conditions of prolonged exposure at 
supraphysiological concentrations. However, anti-angiogenic activity could not be evaluated 
suggesting further investigation in in vivo glioblastoma models. Further studies should also 
assess EGFR expression/drive in GBM cells. 
